Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

Global Prevalence of Diabetes

Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297

β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011

The mechanism of pancreatic secretion

Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,274

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209

Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.

Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995 · cited 2×

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906

The role of incretins in glucose homeostasis and diabetes treatment

Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793

Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications

Afşar, B., Hornum, M., Afşar, R. E., Ertuğlu, L. A., Ortíz, A., Covic, A. C., van Raalte, D. H., Cherney, D. Z. I., & Kanbay, M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.02.016 · Cited by 29

Supplementation with selenium nanoparticles alleviates diabetic nephropathy during pregnancy in the diabetic female rats

Alhazza, I. M., Ebaid, H., Omar, M. S., Hassan, I., Habila, M. A., Al‐Tamimi, J., & Sheikh, M. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-15905-z · Cited by 28

Exenatide improves liver mitochondrial dysfunction and insulin resistance by reducing oxidative stress in high fat diet-induced obese mice

Wang, Z., Hou, L., Huang, L., Guo, J., & Zhou, X. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.010 · Cited by 28

GLP‑1 receptor agonist protects palmitate-induced insulin resistance in skeletal muscle cells by up-regulating sestrin2 to promote autophagy

Tian, X., Gao, Y., Kong, M.-W., Zhao, L., Xing, E., Sun, Q., He, J., Lu, Y., & Feng, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-36602-6 · Cited by 27

Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series

Lajthia, E., Bucheit, J. D., Nadpara, P. A., Dixon, D. L., Caldas, L. M., Murchie, M., & Sisson, E. M. (2019) · Pharmacy Practice · doi:10.18549/pharmpract.2019.4.1588 · Cited by 25

Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes

Liao, W., Lee, W., Chen, C., Lu, C. H., Chen, C.-H., Chou, Y., Lee, I., Sheu, W. H., Wu, J.-Y., Yang, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14951 · Cited by 26

Unraveling the Link between Ιnsulin Resistance and Bronchial Asthma

Bartziokas, Κ., Papaioannou, A. Ι., Drakopanagiotakis, F., Gouveri, E., Παπάνας, Ν., & Steiropoulos, P. (2024) · Biomedicines · doi:10.3390/biomedicines12020437 · Cited by 26

Impaired secretion of glucagon-like peptide 1 during oral glucose tolerance test in patients with newly diagnosed type 2 diabetes mellitus

Wang, X., Ye, F., Li, J., Zhu, L., Feng, G. L., Chang, X., & Sun, K. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.1.12035 · Cited by 27

The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer

Amin, S., Boffetta, P., & Lucas, A. L. (2016) · Gut and Liver · doi:10.5009/gnl15451 · Cited by 25

Glucagon-like peptide-1 receptor agonist exendin 4 ameliorates diabetes-associated vascular calcification by regulating mitophagy through the AMPK signaling pathway

Chen, K., Jin, H., Wu, Z., Zhang, B., Wu, J., Huang, Z., Huang, Y., Lu, X., & Zheng, X.-T. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00817-8 · Cited by 28

Liraglutide Promotes Cortical Neurite Outgrowth via the MEK–ERK Pathway

Li, M., Li, S., & Li, Y. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0193-7 · Cited by 24

Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention

Orabi, D., Berger, N. A., & Brown, J. M. (2021) · Cancers · doi:10.3390/cancers13143473 · Cited by 25

Insulin sensitizers improve the GLP-1 secretion and the amount of intestinal L cells on high-fat-diet–induced catch-up growth

Zheng, J., Xiao, K., Chen, L., Wu, C., Hu, X., Zeng, T., Chen, X.-Q., Li, W., Deng, X., Li, H., et al. (2017) · Nutrition · doi:10.1016/j.nut.2017.01.002 · Cited by 24

The role of GLP-1 signaling in hypoglycemia due to hyperinsulinism

Danowitz, M., & De Leon, D. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.863184 · Cited by 23

Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era

Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 25

Diabetes Mellitus and Prediabetes on Kidney Transplant Waiting List- Prevalence, Metabolic Phenotyping and Risk Stratification Approach

Guthoff, M., Vosseler, D., Langanke, J., Nadalin, S., Königsrainer, A., Häring, H., Fritsche, A., & Heyne, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134971 · Cited by 22

The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5′-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions

Miao, X., Gu, Z., Liu, Y., Jin, M., Lu, Y., Gong, Y., Li, L., & Li, C. (2017) · Peptides · doi:10.1016/j.peptides.2017.07.006 · Cited by 24

Glucagon-like peptide 1 protects INS-1E mitochondria against palmitate-mediated beta-cell dysfunction: a proteomic study

Ciregia, F., Giusti, L., Ronci, M., Bugliani, M., Piga, I., Pieroni, L., Rossi, C., Marchetti, P., Urbani, A., & Lucacchini, A. (2015) · Molecular BioSystems · doi:10.1039/c5mb00022j · Cited by 23

GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer

Srinivasan, N. M., Farokhnia, M., Farinelli, L. A., Ferrulli, A., & Leggio, L. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf141 · Cited by 26

Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme

Mathieu, C., Prato, S. D., Botros, F. T., Thieu, V. T., Pavo, I. J., Jia, N., Haupt, A., Karanikas, C. A., & García‐Pérez, L. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13313 · Cited by 21

Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes

Martins, E. B., Lima, E. G., Pitta, F. G., Carvalho, L. N. S., de Queiroz, T. D., & Junior, C. V. S. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.9.1283 · Cited by 23

Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)

Dahlqvist, S., Ahlén, E., Filipsson, K., Gustafsson, T. P., Hirsch, I. B., Tuomilehto, J., Imberg, H., Åhrén, B., Attvall, S., & Lind, M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000464 · Cited by 24

GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis

Tan, Y. W., Shang, M., Davis, S., & Gananadha, S. (2025) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-025-03831-4 · Cited by 21

Loureirin B activates GLP‐1R and promotes insulin secretion in Ins‐1 cells

Ding, Y., Xia, S., Zhang, H., Chen, Q., & Niu, B. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16138 · Cited by 19

Effects of treatment with Glucagon‐like peptide‐1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta‐analysis

Wang, W., Wei, R., Huang, Z., Luo, J., Pan, Q., & Guo, L. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3680 · Cited by 22

Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes

Saulsberry, W. J., Coleman, C. I., Mearns, E. S., Zaccaro, E., Doleh, Y., & Sobieraj, D. M. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12698 · Cited by 20

GPCRs, G Proteins, and Their Impact on β‐cell Function

Kowluru, A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190028 · Cited by 20

Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes

Bhailis, A. M. D., Azmi, S., & Kalra, P. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211020664 · Cited by 18

Efficacy of combination therapy with GABA, a DPP-4i and a PPI as an adjunct to insulin therapy in patients with type 1 diabetes

Rabinovitch, A., Koshelev, D., Lagunas‐Rangel, F. A., Kosheleva, L., Gavra, T., Schiöth, H. B., & Levit, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1171886 · Cited by 18

Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression

Holliday, M. W., Frost, L. A., & Navaneethan, S. D. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000976 · Cited by 19

The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells

Onuma, H., Inukai, K., Kitahara, A., Moriya, R., Nishida, S., Tanaka, T., Katsuta, H., Takahashi, K., Sumitani, Y., Hosaka, T., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.136 · Cited by 19

Actions of PGLa-AM1 and its [A14K] and [A20K] analogues and their therapeutic potential as anti-diabetic agents

Owolabi, B. O., Musale, V., Ojo, O. O., Moffett, R. C., McGahon, M. K., Curtis, T. M., Conlon, J. M., Flatt, P. R., & Abdel‐Wahab, Y. H. A. (2017) · Biochimie · doi:10.1016/j.biochi.2017.04.004 · Cited by 19

Glucagon-Like Peptide-1 Receptor Agonist and Glucagon Increase Glucose-Stimulated Insulin Secretion in Beta Cells via Distinct Adenylyl Cyclases

Lee, Y.-S., & Jun, H. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.24492 · Cited by 19

Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions

Mehta, K., Behl, T., Kumar, A., Uddin, M. S., Zengin, G., & Arora, S. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721999201208195901 · Cited by 21

Effect of liraglutide on epicardial adipose tissue thickness with echocardiography in patients with obese type 2 diabetes mellitus

Li, Y., Liu, X., Li, G., & Zhang, P. (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00820-9 · Cited by 18

Salmonella Infection Causes Hyperglycemia for Decreased GLP-1 Content by Enteroendocrine L Cells Pyroptosis in Pigs

Zong, Y., Chen, W., Zhao, Y., Suo, X., & Yang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031272 · Cited by 20

The Anti-Inflammatory Effects of Glucagon-Like Peptide Receptor Agonist Lixisenatide on the Retinal Nuclear and Nerve Fiber Layers in an Animal Model of Early Type 2 Diabetes

Chung, Y. W., Lee, J., Lee, J. Y., Ju, H. H., Lee, Y., Jee, D. H., Ko, S., & Choi, J. A. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.01.011 · Cited by 18

New Agents for the Treatment of Type 2 Diabetes

Libianto, R., & Ekinci, E. I. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.007 · Cited by 18

Triple drug therapy with GABA, sitagliptin, and omeprazole prevents type 1 diabetes onset and promotes its reversal in non-obese diabetic mice

Lagunas‐Rangel, F. A., Koshelev, D., Nedorubov, A., Kosheleva, L., Trukhan, V., Rabinovitch, A., Schiöth, H. B., & Levit, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1028114 · Cited by 17

Chayote pectin regulates blood glucose through the gut-liver axis: Gut microbes/SCFAs/FoxO1 signaling pathways

Guo, Q. H., Wang, X., Ke, J., Hou, X., Shen, G., Li, S., Chen, H., Cui, Q., Yu, J., Luo, Q., et al. (2025) · Food Research International · doi:10.1016/j.foodres.2025.115706 · Cited by 18

In Silico Molecular Docking and Dynamic Investigations of Bioactive Phytoconstituents from Fenugreek Seeds as a Potent Drug against DPP-IV Enzyme

Sarker, D. K., Ray, P., Rouf, R., Shilpi, J. A., & Uddin, S. J. (2023) · ACS Food Science & Technology · doi:10.1021/acsfoodscitech.3c00102 · Cited by 16

Semaglutide exposure and its association with adverse outcomes in diabetic patients undergoing transforaminal lumbar interbody fusion for lumbar degenerative disc disease

Khalid, S. I., Massaad, E., Thomson, K. B., & Shin, J. H. (2024) · Journal of Neurosurgery Spine · doi:10.3171/2024.6.spine24141 · Cited by 17

A comparison of the anti-diabetic potential of d-ribose-l-cysteine with insulin, and oral hypoglycaemic agents on pregnant rats

Osinubi, A. A., Medubi, L. J., Akang, E. N., Sodiq, L. K., Samuel, T. A., Kusemiju, T. O., Osolu, J., Madu, D., & Fasanmade, O. A. (2018) · Toxicology Reports · doi:10.1016/j.toxrep.2018.08.003 · Cited by 16

Therapeutic Challenges in Diabetes Prevention: We Have Not Found the “Exercise Pill”

Srinivasan, S., & Florez, J. C. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.146 · Cited by 15

Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys

Cui, Q., Liao, Y., Jiang, Y., Huang, X., Tao, W., Zhou, Q., Shao, A., Zhao, Y., Li, J., Ma, A., et al. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0255 · Cited by 16

Strengthening Semaglutide-GLP-1R Binding Affinity via a Val27-Arg28 Exchange in the Peptide Backbone of Semaglutide: A Computational Structural Approach

Li, W. (2021) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416521500289 · Cited by 14

Pharmacologic Weight Management in the Era of Adolescent Obesity

Raman, V. S., Gupta, A., Ashraf, A. P., Breidbart, E., Gourgari, E., Kamboj, M. K., Kohn, B., Krishnan, S., Lahoti, A., Matlock, K. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac418 · Cited by 15

Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity

Ge, D., Foer, D., & Cahill, K. N. (2022) · Pulmonary Therapy · doi:10.1007/s41030-022-00211-x · Cited by 14

Evidence Report on the Safety of Gastrointestinal Endoscopy in Patients on Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis

Tarar, Z. I., Farooq, U., Chaudhry, A., Gandhi, M. H., Alayli, A. E., Ayoub, M., Singh, B., Daglilar, E. S., & Thosani, N. C. (2025) · Diagnostics · doi:10.3390/diagnostics15060770 · Cited by 15

Potential cardioprotective action of GLP-1: from bench to bedside

Aronis, K. N., Tsoukas, M. A., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.009 · Cited by 14

The Synergistic Effect of Glucagon-Like Peptide-1 and Chamomile Oil on Differentiation of Mesenchymal Stem Cells into Insulin-Producing Cells.

Saghahazrati, S., Ayatollahi, S. A., Kobarfard, F., & Zangii, B. M. (2020) · PubMed Central · doi:10.22074/cellj.2020.6325 · Cited by 14

Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children

Zaitoon, H., Wauters, A. D., Rodríguez, L. M., & Lynch, J. L. (2025) · Children · doi:10.3390/children12111427 · Cited by 15

The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology

Echeverry-Guerrero, S., González-Vélez, S., Arévalo-Lara, A.-S., Calvache-Orozco, J.-C., Villarroel-Hagemann, S. K., Rojas-Rodríguez, L. C., Pérez-Acosta, A. M., & Calderón‐Ospina, C. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3040025 · Cited by 19

Insulin modulates the strong reinforcing effects of nicotine and changes in insulin biomarkers in a rodent model of diabetes

Cruz, B., Flores, R. J., Uribe, K. P., Espinoza, E. J., Spencer, C. T., Serafine, K. M., Nazarian, A., & O’Dell, L. E. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0306-3 · Cited by 14

An Integrated In Silico and In Vitro Assays of Dipeptidyl Peptidase-4 and α-Glucosidase Inhibition by Stellasterol from Ganoderma australe

Budipramana, K., Junaidin, J., Wirasutisna, K. R., Pramana, Y. B., & Sukrasno, S. (2019) · Scientia Pharmaceutica · doi:10.3390/scipharm87030021 · Cited by 13

Effect of 9 - PAHSA on cognitive dysfunction in diabetic mice and its possible mechanism

Wen, X., Guo, Q., & Guo, J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.071 · Cited by 13

Glucagon-like peptide-1 receptor agonist and new-onset diabetes in overweight/obese individuals with prediabetes: A systematic review and meta-analysis of randomized trials

Yanto, T. A., Vatvani, A. D., Hariyanto, T. I., & Suastika, K. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103069 · Cited by 12

Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease

Weng, J., Alizadeh, M. A., & Friedman, S. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09344-w · Cited by 15

PYY (3-36) protects against high fat feeding induced changes of pancreatic islet and intestinal hormone content and morphometry

Sridhar, A., Khan, D., Flatt, P. R., Irwin, N., & Moffett, R. C. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130359 · Cited by 12

Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials

Gomes, D., Presume, J., Gonçalves, P. D. A., Almeida, M., Mendes, M., & Ferreira, J. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07547-3 · Cited by 15

Insulinotropic, glucose-lowering, and beta-cell anti-apoptotic actions of peptides related to esculentin-1a(1-21).NH2

Musale, V., Abdel‐Wahab, Y. H. A., Flatt, P. R., Conlon, J. M., & Mangoni, M. L. (2018) · Amino Acids · doi:10.1007/s00726-018-2551-5 · Cited by 12

Cross-Talk between Obesity and Diabetes: Introducing Polyphenols as an Effective Phytomedicine to Combat the Dual Sword Diabesity

Shah, M. A., Haris, M. N., Faheem, H. I., Hamid, A., Yousaf, R., Rasul, A., Shah, G. M., Khalil, A. A. K., Wahab, A., Khan, H. Z., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220628123224 · Cited by 13

Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide‐analog administration to intensive insulin therapy

Ogawa, S., Nako, K., Okamura, M., Sakamoto, T., & Ito, S. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12314 · Cited by 12

Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes

Niu, C., Sun, K., Zhang, J., Elkhapery, A. M. R., Zhu, K., Malik, S., Xue, C., & Okolo, P. I., III (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003760 · Cited by 15

Management of Hyperglycemia in Hospitalized Patients Receiving Parenteral Nutrition

Schönenberger, K. A., Reber, E., Dürig, C., Baumgartner, A., Efthymiou, A., Huwiler, V. V., Laimer, M. W., Bally, L., & Stanga, Z. G. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.829412 · Cited by 11

Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management

Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 13

Cardiovascular Outcome Trials with Glucose-Lowering Drugs

Thethi, T. K., Bilal, A., & Pratley, R. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01505-3 · Cited by 11

Beta-cell autophagy under the scope of hypoglycemic drugs; possible mechanism as a novel therapeutic target

Marzoog, B. A., & Vlasova, T. I. (2022) · Obesity and metabolism · doi:10.14341/omet12778 · Cited by 12

Costus pictus D. Don leaf extract stimulates GLP-1 secretion from GLUTag L-cells and has cytoprotective effects in BRIN-BD11 β-cells

Patibandla, C., Khan, Z. I., MacGregor, L., Campbell, M. J., & Patterson, S. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112970 · Cited by 11

Combination therapy with dipeptidyl peptidase-4 and P2X7 purinoceptor inhibitors gives rise to antiepileptic effects in rats

Jamali-Raeufy, N., Barati, H., Baluchnejadmojarad, T., Roghani, M., & Goudarzi, M. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101855 · Cited by 11

Effects of Exendin-4 on pancreatic islets function in treating hyperglycemia post severe scald injury in rats

Li, D., Shang, Y., Shen, C., Li, L., Zhao, D., Ma, L., & Yu, Y. (2018) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000002066 · Cited by 11

Small-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives

Sun, X., Zhang, Z., Liu, M., Zhang, P., Nie, L., Liu, Y., Chen, Y., Xu, F., Liu, Z., & Zeng, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112722 · Cited by 10

Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives

Guo, J., Zhou, B., Niu, Y., Liu, L., & Yang, L. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01279-1 · Cited by 10

Hesperidin activates the GLP-1R/cAMP-CREB/IRS2/PDX1 pathway to promote transdifferentiation of islet α cells into β cells Across the spectrum

Zhang, W., Wu, L., Qu, R., Liu, T., Wang, J., Tong, Y., Bei, W., Guo, J., & Hu, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35424 · Cited by 10

Innovative therapeutics for renoprotection: Where we are

Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10

Sortilin-derived peptides promote pancreatic beta-cell survival through CREB signaling pathway

Daziano, G., Blondeau, N., Béraud-Dufour, S., Abderrahmani, A., Rovère, C., Heurteaux, C., Mazella, J., Lebrun, P., & Coppola, T. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105539 · Cited by 11

Immune therapy in type 1 diabetes mellitus — Attempts to untie the Gordian knot?

Perakakis, N., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.016 · Cited by 10

GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus

Dahiya, L., Kaur, R., Kumar, R., Kumar, M., & Palta, K. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190502114924 · Cited by 10

Oxaliplatin reverses the GLP‑1R‑mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling

Chen, B., Zhou, W., Zhao, W., Yuan, P., Tang, C., Wang, G., Leng, J., Ma, J., Wang, X., Hui, Y., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10497 · Cited by 10

Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents

García‐Compeán, D., Kumar, R., del Cueto-Aguilera, Á. N., Maldonado-Garza, H. J., & Villarreal‐Pérez, J. Z. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100751 · Cited by 10

Amphibian host-defense peptides with potential for Type 2 diabetes therapy – an updated review

Conlon, J. M., Owolabi, B. O., Flatt, P. R., & Abdel‐Wahab, Y. H. A. (2024) · Peptides · doi:10.1016/j.peptides.2024.171180 · Cited by 9

Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management

Postlethwaite, R., Amin, A. M., Alsawas, R., Almandoz, J. P., & Sawas, T. (2025) · Pancreatology · doi:10.1016/j.pan.2025.06.018 · Cited by 10

Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes – Case Presentations

Seetharaman, S., & Cengiz, E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305641 · Cited by 9

GPCRs, G Proteins, and Their Impact on β‐cell Function

Kowluru, A. (2020) · Comprehensive physiology · doi:10.1002/j.2040-4603.2020.tb00126.x · Cited by 9

Treatment of Type 2 diabetes with Tianqi Jiangtang Capsule

Piao, C., Zhang, Q., Jin, D., Shao, M., Bi, C., Wang, L., Tang, C. W., Lian, F., & Tong, X. (2020) · Medicine · doi:10.1097/md.0000000000019702 · Cited by 9

Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers

Fukui, K., Kawahito, H., Wakana, N., Kikai, M., Terada, K., Yamamoto, K., Irie, D., Kato, T., Miyagawa, S., & Yamada, H. (2015) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320315587180 · Cited by 9

Clinical Characteristics and Satisfaction of Liraglutide Treatment among Patients with Type 2 Diabetes: A Prospective Study

Hayek, A. A., Robert, A. A., & Dawish, M. A. A. (2019) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551419834935 · Cited by 9

Mof regulates glucose level via altering different α-cell subset mass and intra-islet glucagon-like peptide-1, glucagon secretion

Guo, X., Li, D., Song, J., Yang, Q., Wang, M., Yang, Y., Wang, L., Hou, X., Chen, L., & Li, X. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154290 · Cited by 9

Investigating the Impact of GLP-1 Receptor Agonist-Induced Fat Loss on Collagen Synthesis and Skin Elasticity

Sataray-Rodriguez, A., Pham, D., Severini, C., Oladinni, D., Hunter, C., Marsh, S., Sataray-Arriaga, L., & Frasier, K. M. (2025) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2025.183003 · Cited by 10

GLP-1 and IL-6 regulates obesity in the gut and brain

Yang, K., Wu, Y., He, Y., Dai, J.-X., Luo, Y.-L., Xie, J.-H., & Ding, W. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123339 · Cited by 8

Need for Better Diabetes Treatment: The Therapeutic Potential of NMDA Receptor Antagonists

Welters, A., Lammert, E., Mayatepek, E., & Meißner, T. (2016) · Klinische Pädiatrie · doi:10.1055/s-0042-117831 · Cited by 8

A long-acting, dual-agonist analogue of lamprey GLP-1 shows potent insulinotropic, β-cell protective, and anorexic activities and improves glucose homeostasis in high fat-fed mice

Graham, G. V., McCloskey, A. G., Abdel‐Wahab, Y. H. A., Conlon, J. M., & Flatt, P. R. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110584 · Cited by 8

Vagotomy and subsequent development of diabetes – A nested case–control study

Starup‐Linde, J., Gejl, M., Borghammer, P., Knop, F. K., Gregersen, S., Rungby, J., & Vestergaard, P. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.002 · Cited by 8

Protein restriction during pregnancy impairs intra-islet GLP-1 and the expansion of β-cell mass

de Arruda, E. H. P., da Silva, G. L. V., da Rosa-Santos, C. A., Arantes, V. C., Reis, M. A. D. B., Colodel, É. M., de Moura, E. G., Lisboa, P. C., Carneiro, E. M., Damazo, A. S., et al. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110977 · Cited by 8

Compound 19e, a Novel Glucokinase Activator, Protects against Cytokine-Induced Beta-Cell Apoptosis in INS-1 Cells

Oh, Y. S., Seo, E., Park, K., & Jun, H. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00169 · Cited by 8

Glycemia, Insulin Sensitivity, and Secretion Improve 3 Months Post-sleeve Gastrectomy in Youth With Type 2 Diabetes

Dobbs, T. J., Cree‐Green, M., Bailey, A., Baumgartner, A., Garrish, J., Diniz-Behn, C., Pyle, L., Kelsey, M. M., SHAH, A. S., Inge, T. H., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf020 · Cited by 7

Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis

Lee, B. K., Ghumman, U., Pedicone, L. D., Gómez-Aldana, A., & Lawitz, E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0337 · Cited by 9

Reconfiguration of the small intestine and diabetes remitting effects of Roux-en-Y gastric bypass surgery

Docherty, N. G., & le Roux, C. W. (2016) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000241 · Cited by 7

Glucagon‐like Peptides (GLP‐1) Perspectives in Synucleinopathies Treatment

Foltynie, T., & Athauda, D. S. (2018) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12611 · Cited by 7

Insulinotropic activity of the host-defense peptide frenatin 2D: Conformational, structure-function and mechanistic studies

Musale, V., Guilhaudis, L., Abdel‐Wahab, Y. H. A., Flatt, P. R., & Conlon, J. M. (2018) · Biochimie · doi:10.1016/j.biochi.2018.09.008 · Cited by 7

Glucagon‐like peptide 1‐potentiated insulin secretion and proliferation of pancreatic β‐cells GLP‐1促进胰岛素分泌和胰岛β细胞增殖的机制

Ma, X., Guan, Y., & Hua, X. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12161 · Cited by 35

Effect of glucagon-like peptide-1 on pancreatic β-cells

An, R. (2009) · International Journal of Pathology and Clinical Medicine

Glucagon‐like peptide‐1: modulator of β ‐cell dysfunction and death

Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32

New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells

Xiong, X., Shao, W., & Jin, T. (2012) · Islets · doi:10.4161/isl.23345 · Cited by 27

Insulin receptor signaling and glucagon-like peptide 1 effects on pancreatic beta cells

Caporarello, N., Parrino, C., Trischitta, V., & Frittitta, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181190 · Cited by 12